MN-DIGI-INTL
15.6.2021 15:02:07 CEST | Business Wire | Press release
Digi International (NASDAQ: DGII) (www.digi.com ), a leading global provider of Internet of Things (IoT) connectivity products and services, today announced the expansion of its market-leading ConnectCore® family of products with the introduction of the Digi ConnectCore® 8M Mini System on Module (SOM).
Digi ConnectCore 8M Mini is a highly integrated and cost-effective SOM platform based on the NXP® i.MX 8M Mini applications processor. Featuring the optimal balance of performance, power and cost, it’s designed for mission-critical industrial, medical, transportation and agriculture applications. Digi ConnectCore simplifies embedded product development thanks to integrated memory, power management, pre-certified wireless, advanced security and the complete, open-source Digi Embedded Yocto Linux software platform based on Yocto Project™ or Android-based Digi Embedded Android, setting the product apart and enabling manufacturers to get to market faster with lower risk and cost and to focus on their core competency.
“Digi is excited to be expanding the Digi ConnectCore® family of products," said Steve Ericson, General Manager, OEM Solutions at Digi International. "We remain dedicated to delivering advanced solutions that simplify product development for manufacturers seeking secure, connected products that also help reduce the cost of R&D. The Digi ConnectCore 8M Mini SOM extends that commitment and delivers increased capability while lowering the total cost of ownership.”
With versatile, power-efficient ARM® Cortex® -A53 and Cortex-M4 processing cores, rich multimedia (2D/3D GPU, VPU, MIPI-DSI/CSI, SAI, PDM) and advanced connectivity (802.11 ac, Bluetooth 5, Gigabit Ethernet), the Digi ConnectCore 8M Mini is ideal for Internet of Things (IoT), human-machine interface (HMI), equipment monitoring, audio/voice, edge computing and machine learning applications.
Security and longevity are at the heart of the Digi ConnectCore 8M Mini’s design. Digi TrustFence® delivers a tested and fully integrated device security framework designed for the long product life cycle of embedded devices. Additionally, the i.MX 8M Mini processor is industrial qualified and backed by NXP’s Product Longevity Program, ensuring long-term availability of 10-plus years.
The Digi ConnectCore 8M Mini’s feature set makes it the only SOM among its competitors to offer Bluetooth 5 compatibility and cellular enablement, as well as Digi’s proprietary TrustFence security framework. At 40 x 45 x 3.5 mm, its physical hardware size is also among the smallest in the industry. Access a full list of additional Digi 8M Mini features here .
Availability
Initial Digi ConnectCore 8M Mini development kits and software will be available through global distribution partners June 15, 2021.
About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services and solutions. We help our customers create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, we’ve helped our customers connect over 100 million things and growing. For more information, visit Digi's website at www.digi.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210615005035/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enhertu® Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer1.9.2026 08:30:00 CEST | Press release
Approval based on DESTINY-Breast09 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus THP with a median progression-free survival exceeding three years Second approval for Enhertu in the EU in two months Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results fro
Paris Hilton Returns as the Face of KARL LAGERFELD as NOT-KARL Debuts for Fall–Winter 20261.9.2026 08:30:00 CEST | Press release
Following the success of the Maison's Fall-Winter 2025 and Spring-Summer 2026 campaigns, KARL LAGERFELD is delighted to announce the extension of its relationship with global entrepreneur, media personality and cultural icon Paris Hilton, continuing a partnership that has resonated with audiences around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831566835/en/ KARL LAGERFELD - Paris Hilton ©Matt Easton As the face of the Maison through Fall-Winter 2026 and Spring-Summer 2027, Paris Hilton returns for the next chapter of KARL LAGERFELD's From Paris With Love story, continuing to bring her signature confidence, wit and individuality. Photographed for the first time by Matt Easton, the Fall-Winter 2026 campaign introduces a new dimension to the narrative while remaining true to the House's established codes. At the heart of the Fall-Winter 2026 story, two masters of self-reinvention meet. Making his debut is NO
Flashnet Partners with Netmore in Strategic Global Partnership for Smart Street Lighting1.9.2026 08:00:00 CEST | Press release
Collaboration combines carrier-grade LoRaWAN® connectivity with award-winning smart street lighting technology to accelerate smart city transformation Netmore Group, the leading network operator and platform provider for Massive IoT, today announced that Flashnet, a Lucy Group company and global leader in intelligent street lighting solutions, has joined Netmore's Pulse Partner Program. The partnership marks another important milestone in Netmore's growing ecosystem, combining best-in-class connectivity with proven smart infrastructure solutions to accelerate the digital transformation of cities and utilities around the world. Driven by rapid urbanisation, government sustainability mandates, and the accelerating rollout of smart city programs worldwide, smart street lighting is increasingly recognized as the entry point for smart city transformation and one of the fastest-growing segments of the global IoT infrastructure market. As municipalities and utilities continue to modernize cri
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the
Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 04:00:00 CEST | Press release
Milestone-based government program supports multiple fusion approaches toward power demonstration and commercialization Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated ove
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom